Eli Lilly is allowing more patients early access to its experimental weight loss drug

The drugmaker said it will review requests from doctors for patients who cannot enroll in a clinical trial

Drugmaker Eli Lilly says it is expanding access to its experimental weight loss drug, retatrutide, which has not been approved yet by the FDA. The company says obese patients taking the drug in clinical trials lost between 73 and 85 pounds over two years. Dr. Rachel Pessah Pollack discusses what we know about its safet

Eli Lilly confirmed that it will allow more patients to apply for early access to retatrutide, an unapproved obesity drug

A breast cancer surgeon explains how GLP-1 drugs like Ozempic and Wegovy may lower cancer recurrence risk by reducing BMI, estrogen and inflammation.

Eli Lilly to offer early access to next-gen obesity drug to some patients  Reuters

J. Vespa/WireImage Remember the Titans actor Ethan Suplee slammed a mistake many GLP-1 users make, using his remarkable weight-loss journey as a reference point. Suplee peaked at 536 pounds in 2001, then lost a mind-boggling 300 pounds through diet and lifestyle changes. “As a kid, I wanted a magical diet drug so badly

Jaime says TikTok taught her how to buy and inject black market peptides. Months later, she had lost 17kg.